Salvage lenalidomide in four rare oncological diseases
| Authors | |
|---|---|
| Year of publication | 2013 |
| Type | Peer-reviewed scientific article |
| Magazine / Source | Tumori |
| MU Faculty or unit | |
| Citation | |
| web | http://www.tumorionline.it/articoli.php?archivio=yes&vol_id=1377&id=15326 |
| Doi | https://doi.org/10.1700/1377.15326 |
| Field | Oncology and hematology |
| Keywords | Langerhans cell histiocytosis; Erdheim-Chester disease; angiomatosis; Castleman disease |
| Description | In rare disorders, there are often no standard therapy recommendations. Patients with refractory disease may require novel experimental approaches. Applied as second- up to fourth-line treatment, lenalidomide (10-25 mg perorally on days 1-21 in a 28-day cycle) was used in our cohort of four adult patients with aggressive, multisystem and relapsing diseases. Complete and long-lasting remissions (more than 1 year, no maintenance therapy) were achieved in patients with Langerhans cell histiocytosis (11 cycles, combination with dexamethasone and etoposide, consolidated by allogeneic blood stem cell transplant) and plasma-cell Castleman disease (15 cycles, monotherapy). Mixed response with complete disappearance of brain infiltrates was reached in Erdheim-Chester disease (6 cycles, monotherapy) and gastrointestinal bleeding was well controlled in multiple angiomatosis (9 cycles, combination with thalidomide). For disease activity evaluation each patient underwent fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography scan imaging, which was complemented by clinical and laboratory investigations. |
| Related projects: |
|